Pharmacologic Stress Agents: A New Era CME

Author Information and Disclosures

Release Date: September 30, 2008; Valid for credit through September 30, 2009

Credits Available
Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Astellas
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Discuss the available agents for use in pharmacologic stress testing in the detection of coronary artery disease (CAD)
  2. Describe the potential role of newly emerging adenosine A2a agonist stress agents in improving the characterization and management of suspected coronary artery disease
  3. Define best practices for use of adenosine A2a agonist stress agents in concert with radionuclide imaging to improve the assessment of coronary artery disease
Authors and Disclosures

Manuel Cerqueira, MD, FACC, FAHA, FASNC
Disclosure: Manuel Cerqueira, MD, FACC, FAHA, FASNC, has disclosed that he has served as an advisor or consultant for GE Healthcare, Astellas Pharma, Covidien, Lantheus Medical Imaging, and Siemens. Dr. Cerqueira has also disclosed that he has served on the speaker’s bureau for GE Healthcare and Covidien.


John J. Mahmarian, MD, FACC, FASNC
Disclosure: John J. Mahmarian, MD, FACC, FASNC, has disclosed that he has received grants for clinical research and served as an advisor or consultant for Astellas and CV Therapeutics.


James Udelson, MD
Disclosure: James Udelson, MD, has disclosed that he has served as an advisor or consultant for, and received grants for clinical research from, King Pharmaceuticals R&D.


Robert Chevrier
Disclosure: Robert Chevrier has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.